SCHEMBL6004113

SCHEMBL6004113

Cc1ccc(S(=O)(=O)OCCC(c2ccc(Cl)cc2)(c2ccc(Cl)cc2)c2ccc(Cl)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 1/20 0.42
ENPP1 P22413 1/20 0.42
ENPP2 Q13822 1/20 0.42
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
CNR2 P34972 1/20 0.40
KMT2A Q03164 5/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 3/20 0.38
HTT P42858 2/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6005376 0.85 KIF11 (0.47) BCHEACHEKMT2AMEN1GAA
SCHEMBL10838189 0.79 GRIN2D (0.43) ENPP3ENPP1ENPP2BCHEACHE
SCHEMBL948326 0.79 CNR2 (0.56) BCHEACHECNR2KMT2AEGFR
SCHEMBL6002078 0.78 ALDH1A1 (0.43) KMT2AMEN1ALDH1A1GAACA12
SCHEMBL1502260 0.78 STAT3 (0.44) KMT2AMEN1ALDH1A1GAACA12
SCHEMBL11022325 0.78 ENPP3 (0.43) ENPP3ENPP1ENPP2BCHEACHE
SCHEMBL1332078 0.78 CA12 (0.56) ENPP3ENPP1ENPP2BCHEACHE
SCHEMBL241884 0.77 CA1 (0.52) KMT2AALDH1A1GAACA12CA1
SCHEMBL7723972 0.77 CNR2 (0.54) BCHEACHECNR2KMT2AEGFR
SCHEMBL283201 0.76 CA12 (0.42) BCHEACHEKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. 2006-12-21 US disclosed
EP-1014966-B1 PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS ALLELIX NEUROSCIENCE INC (US) 2006-08-02 EP disclosed
US-7019024-B2 Pharmaceutical for treatment of neurological and neuropsychiatric disorders ALLELIX NEUROSCIENCE INC. (US) 2006-03-28 US disclosed
US-6191165-B1 ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS ALLELIX NEUROSCIENCE INC. 2001-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287298-A1 Pharmaceutical for treatment of neurological and neuropsychiatric disorders SLC18A2, SLC6A1, SLC6A11 ENPP3 1654/4885ENPP1 1572/4885ENPP2 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.